Other abnormal tumor markers
ICD-10 R97.8 is a billable code used to indicate a diagnosis of other abnormal tumor markers.
The ICD-10 code R97.8 is used to classify abnormal tumor markers that do not fall under specific categories defined by other codes. Tumor markers are substances, often proteins, produced by cancer cells or by the body in response to cancer. They can be detected in blood, urine, or tissues and are used primarily for diagnosis, monitoring treatment response, and assessing recurrence. Abnormal levels of tumor markers can indicate various malignancies or other conditions, but the presence of these markers alone is not diagnostic of cancer. Common tumor markers include CA-125, PSA, and CEA, among others. The interpretation of abnormal results requires careful clinical correlation and consideration of the patient's overall clinical picture. This code is particularly relevant when the specific tumor marker is not classified elsewhere, necessitating a broader categorization for coding purposes.
Detailed clinical history, lab results, and correlation with physical examination findings.
Patients presenting with abnormal lab results during routine check-ups or follow-ups for known malignancies.
Ensure that the abnormal marker is documented in the context of the patient's overall health status and any ongoing treatment.
Acute care documentation must include immediate lab results and any relevant history.
Patients presenting with acute symptoms that may correlate with abnormal tumor markers, such as pain or unexplained weight loss.
Rapid assessment and documentation are crucial; ensure that abnormal findings are linked to the presenting complaint.
When a tumor marker test is performed to evaluate a patient's cancer status.
Document the specific tumor marker tested and the reason for testing.
Oncology practices may frequently order these tests, requiring precise documentation.
Use R97.8 when a patient has abnormal tumor markers that do not fit into more specific categories. Ensure that there is adequate documentation linking the abnormal markers to the patient's clinical condition.
